IMARC Group, a leading market research company, has recently releases report titled “Pharmaceutical Continuous Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028. The report offers a comprehensive analysis of the industry, which comprises insights on the global pharmaceutical continuous manufacturing market share. The global pharmaceutical continuous manufacturing market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.6% during 2023-2028.
Pharmaceutical continuous manufacturing is a cutting-edge production process within the pharmaceutical industry that involves the uninterrupted and automated production of pharmaceutical drugs. It heavily relies on automation and real-time monitoring to maintain precise control over drug formulation and quality. It ensures a seamless flow of raw materials through various stages, resulting in a more efficient and consistent drug manufacturing process. It offers enhanced quality control through continuous monitoring and adjustments, ensuring consistent drug quality. It reduces production time, operational costs, and resource wastage due to its continuous and automated nature. It requires minimal manual handling and exposure to potent compounds, which enhances operator safety. It aligns with sustainability goals by reducing energy consumption and waste generation. It is widely employed in the production of a wide range of pharmaceutical drugs, including tablets, capsules, and oral solid dosage forms. It is increasingly applied in the manufacturing of biopharmaceuticals, such as monoclonal antibodies and vaccines. Besides this, it is also utilized in the production of drugs containing highly potent or toxic compounds for enhanced safety. Moreover, as it enables the efficient production of personalized medicines tailored to individual patient needs, the demand for pharmaceutical continuous manufacturing is increasing across the globe.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/pharmaceutical-continuous-manufacturing-market/requestsample
Pharmaceutical Continuous Manufacturing Market Trends and Drivers:
The rising need for greater efficiency and cost-effectiveness in drug production represents one of the primary factors influencing the market positively. Apart from this, the rising shift towards personalized medicine and the development of complex biopharmaceuticals, including monoclonal antibodies and cell and gene therapies, are strengthening the growth of the market. Furthermore, the strict regulatory environment governing the pharmaceutical industry is favoring the adoption of continuous manufacturing. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are providing support for continuous manufacturing as it allows for real-time monitoring and quality control, ensuring the production of safe and consistent pharmaceuticals. The implementation of Quality by Design (QbD) principles is also encouraging pharmaceutical companies to adopt continuous manufacturing to achieve better process understanding and control, leading to improved product quality. Moreover, the growing environmental concerns are promoting the adoption of continuous manufacturing due to its reduced resource consumption and waste generation. Additionally, the advent of advanced technologies, such as process analytical technology (PAT) and digitalization, is driving innovation in pharmaceutical continuous manufacturing. PAT enables real-time monitoring and control of manufacturing processes, ensuring product quality and consistency. The integration of digital technologies, including artificial intelligence (AI) and machine learning, is enhancing process optimization and predictive maintenance, making continuous manufacturing even more efficient and reliable.
Competitive Landscape with Key Player:
- Baker Perkins
- Coperion GmbH (Hillenbrand Inc.)
- Eli Lilly and Company
- GEA Group Aktiengesellschaft
- Glatt GmbH
- Korsch AG
- Novartis AG
- Siemens
- SK biotek
- Thermo Fisher Scientific Inc.
- Viatris Inc.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Therapeutics Type:
- Large Molecules
- Small Molecules
Breakup by Formulation:
- Solid Formulation
- Liquid and Semi-solid Formulation
Breakup by Application:
- Final Drug Product Manufacturing
- API Manufacturing
Breakup by End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800\
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal